News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Hadasit Bio Holdings Portfolio Company Tolarex Ltd. to Commence Phase I/IIa Trial of a Treatment for GVHD


4/20/2009 9:20:12 AM

EIN KEREM, Israel--(BUSINESS WIRE)--Tolarex, a Hadasit Bio Holdings Ltd (HBL) portfolio company, announced today that it has received approval by the Ministry of Health of Israel to begin a phase I/IIa clinical trial of its treatment for graft-versus-host disease (GVHD).

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES